Product Description
The VXB-241 vaccine candidate targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), a major cause of severe respiratory diseases in young children and older adults. (Sourced from: https://vicebio.com/pipeline-2/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vicebio Australia Proprietary Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|